Shionogi To Invest In New Research Facility And Consolidate Kansai Bases
This article was originally published in PharmAsia News
Executive Summary
Shionogi announced Jan. 28 plans to invest ¥14 billion toward building a new research facility in Fuchu, Osaka. Shionogi will consolidate its three research facilities currently spread throughout the Kansai area - Osaka City, Setsu City and Kouka City - and move around 700 researchers into the new facility, in which drug development and safety research will be conducted. The new facility is scheduled to begin operation in summer 2010. Takeda, another Osaka-based pharmaceutical giant, has set up a new research institute in Kanagawa prefecture. (Click here for more-Japanese language
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.